Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy

Cancer

Volumn 115, Issue 5, 2009, Pages 962-971

  Yi, Min ^a   Meric Bernstam, Funda ^a   Middleton, Lavinia P ^a   Arun, Banu K ^a   Bedrosian, Isabelle ^a   Babiera, Gildy V ^a   Hwang, Rosa F ^a   Kuerer, Henry M ^a   Yang, Wei ^a   Hunt, Kelly K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Contralateral breast cancer; Contralateral prophylactic mastectomy; Ipsilateral; Unilateral breast cancer

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; METASTASIS; PATIENT CODING; PATIENT IDENTIFICATION; PREDICTOR VARIABLE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CASE-CONTROL STUDIES; DECISION MAKING; FEMALE; HUMANS; MASTECTOMY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 61449134181     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24129     Document Type: Article

References (39)

1. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101:1977-1986.
2. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23: 4275-4286.
3. Kollias J, Ellis IO, Elston CW, Blarney RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. 1999;25:584-589.
4. Robbins GF, Berg JW. Bilateral primary breast cancer, a prospective clinicopathological study. Cancer. 1964; 17: 1501-1527.
5. Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6:546-552.
6. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19:3938-3943.
7. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287-292.
8. Peralta EA, Ellenhom JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180:439-445.
9. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107:1440-1447.
10. Bondy ML, Lustbader ED, Halabi S, Ross E, Vogel VG. Validation of a breast cancer risk assessment model in women with a positive family history. J Natl Cancer Inst. 1994;86:620-625.
11. Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541 -1548.
12. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81:1879-1886.
13. Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst. 2001;93:358-366.
14. Spiegelman D, Colditz GA, Hunter D, Hertzmark E. Validation of the Gail et al model for predicting individual breast cancer risk. J Natl Cancer Inst. 1994;86:600-607.
15. Kulkarni S Rademaker A, Khan S, Staradub V, Wiley L. Breast cancer risk correlates with level of atypia in prophylactic mastectomy (PM) specimens. Ann Surg Oncol. 2004; 11 (suppl 2):S94.
16. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control, 1974;19:716-723.
17. Gershenwald. JE, Hunt KK, Kroll SS, et al. Synchronous elective contralateral mastectomy and immediate bilateral breast reconstruction in women with early-stage breast cancer. Ann Surg Oncol. 1998;5:529-538.
18. Nielsen M, Christensen L, Andersen J. Contralateral cancerous breast lesions in women with clinical invasive breast carcinoma. Cancer. 1986;57:897-903.
19. Wanebo HJ, Senofsky GM, Fechner RE, Kaiser D, Lynn S, Paradies J. Bilateral breast cancer. Risk reduction by contralateral biopsy. Ann Surg. 1985;201:667-677.
20. Giuliano AE, Boolbol S, Degnim A, Kuerer H, Leitch AM, Morrow M. Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007. Ann Surg Oncol. 2007;14:2425-2427.
21. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol, 2007;25:5203-5209.
22. Erdreich LS, Asai NR, Hoge AF. Morphologic types of breast cancer: age, bilaterality, and family history. South Med J. 1980;73:28-32.
23. Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am Surg. 1993;59:733-735.
24. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6:R149-R156.
25. Lesser ML, Rosen PP, Kinne DW. Multicentricity and bilaterality in invasive breast carcinoma. Surgery. 1982;91: 234-240.
26. Newman LA, Sahin AA, Cunningham JE, et al. A case-control study of unilateral and bilateral breast carcinoma patients. Cancer. 2001;91:1845-1853.
27. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in women treated for earlystage breast cancer: a population-based study. Int J Radiat Oncol Biol Phys. 2003;56:1038-1045.
28. Alberg AJ, Singh S. Epidemiology of breast cancer in older women: implications for future healthcare. Drugs Aging. 2001;18:761-772.
29. Bodian CA, Perzin KH, Lattes R, Hoffmann P, Abemathy TG. Prognostic significance of benign proliferative breast disease. Cancer. 1993;71:3896-3907.
30. Dupont WD, Parl FF, Hartmann WH, et al. Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. Cancer. 1993;71:1258-1265.
31. London SJ, Connolly JL, Schnitt SJ, Colditz GA. A prospective study of benign breast disease and the risk of breast cancer. JAMA. 1992;267:941-944.
32. Marshall LM, Hunter DJ, Connolly JL, et al. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev. 1997; 6:297-301.
33. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361:125-129.
34. Shaaban AM, Sloane JP, West CR, et al. Histopathologic types of benign breast lesions and the risk of breast cancer: case-control study. Am J Surg Pathol. 2002;26:421-430.
35. Singletary SE. A working model for the time sequence of genetic changes in breast tumorigenesis. J Am Coll Surg. 2002;194:202-216.
36. Newsham IF. The long and short of chromosome 11 in breast cancer. Am J Pathol. 1998;153:5-9.
37. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356:1295-1303.
38. Rutqvist LE, Cedermark B, Glas U, et al. Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst. 1991;83: 1299-1306.
39. Stewart HJ. The Scottish trial of adjuvant tamoxifen in lymph node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr. 1992; 117-120.